Advances in the Management of Diabetes and Overweight using
Incretin-based Pharmacotherapies

Shatrudhan      Prajapati
doi:10.2174/0115733998256797231009062744
Abstract

Throughout the previous three decades, the secretion of glucagon-like peptide-1 hormone has attracted much attention to attain possible therapy goals for the treatment of both hypoglycaemic along type II diabetes militates and overweight. The pharmaceutical generation of peptides similar to hypoglycaemia-based medicines is exemplified by agonists of the GLP- 1R (Glucagon-like peptide-1 receptors). Pharmacokinetic profiles are continuously being improved, beginning with the native hormone with a two- to three-minute quarter and progressing through growth every day with once-drug combinations. Due to contradictory data that indicate stimulation or inhibition of the Glucagon-like peptide receptor, the Glucose-dependent insulin tropic peptide receptor offers favorable effects on systemic metabolism. The recent Glp-1R (Glucagon-like peptide-1 receptor-) targeting monomolecular drugs has demonstrated therapeutic effectiveness and has stoked interest in Glucose-dependent insulin tropic polypeptide antagonism as a treatment for overweight and diabetes mellitus. These drugs have been shown to dramatically improve carbohydrates with body weight management in sick people who have obesity and type II diabetes mellitus. In this study, recent breakthroughs in compelling therapeutic interventions are discussed, and the biology and pharmacology of the glucose-like peptide are reviewed.
[1]
Ganawa S, Santhosh SH, Parry L, Syed AA. Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome. Clin Obes  2022; 12(5): e12546.
 [http://dx.doi.org/10.1111/cob.12546] [PMID:  35932204]

[2]
Reilly JJ, Kelly J. Long-term impact of childhood obesity on adult morbidity and premature mortality: Systematic review. Int J Obes  2011; 35: 891-8.
 [http://dx.doi.org/10.1038/ijo.2010.222]

[3]
Yusefzadeh H, Rashidi A, Rahimi B. Economic burden of obesity: A systematic review. Soc Health Behav  2019; 2(1): 7.

[4]
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol  2012; 8(4): 228-36.
 [http://dx.doi.org/10.1038/nrendo.2011.183] [PMID:  22064493]

[5]
Candler TP, Mahmoud O, Lynn RM, Majbar AA, Barrett TG, Shield JPH. Continuing rise of type 2 diabetes incidence in children and young people in the UK. Diabet Med  2018; 35(6): 737-44.
 [http://dx.doi.org/10.1111/dme.13609] [PMID:  29460341]

[6]
Fremlin GA, Orpin S, Kaur MR. Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. Clin Exp Dermatol  2017; 42(8): 913-4.
 [http://dx.doi.org/10.1111/ced.13199]

[7]
Magliano DJ, Sacre JW, Harding JL, Gregg EW, Zimmet PZ, Shaw JE. Young-onset type 2 diabetes mellitus — implications for morbidity and mortality. Nat Rev Endocrinol  2020; 16(6): 321-31.
 [http://dx.doi.org/10.1038/s41574-020-0334-z] [PMID:  32203408]

[8]
Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: A matter of oxygen? Front Endocrinol (Lausanne)  2015; 6: 55.
 [http://dx.doi.org/10.3389/fendo.2015.00055]

[9]
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: Advances and challenges. Nat Rev Drug Discov  2022; 21(3): 201-23.
 [http://dx.doi.org/10.1038/s41573-021-00337-8] [PMID:  34815532]

[10]
Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes  2015; 39(8): 1188-96.
 [http://dx.doi.org/10.1038/ijo.2015.59] [PMID:  25896063]

[11]
Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond)  2016; 130(12): 943-86.
 [http://dx.doi.org/10.1042/CS20160136]

[12]
Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev  2017; 18(6): 603-34.
 [http://dx.doi.org/10.1111/obr.12531] [PMID:  28346723]

[13]
Babiker A, Al Dubayee M. Anti-diabetic medications Laurence–Moon– Bardet-Biedl syndrome disorder. Sudan J Paediatr  2017; 17(2): 11.
 [http://dx.doi.org/10.24911/SJP.2017.2.12] [PMID:  29545660]

[14]
Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med  2016; 14(1): 10.
 [http://dx.doi.org/10.1186/s12916-016-0553-2] [PMID:  26843061]

[15]
Comerma-Steffensen S, Grann MU, Andersen C, Rungby J, Simonsen U. Cardiovascular effects of current and future anti-obesity drugs. Curr Vasc Pharmacol  2014; 12(3): 493-504.
 [http://dx.doi.org/10.2174/1570161112666140423223529]

[16]
Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med  2022; 70(1): 5-13.
 [http://dx.doi.org/10.1136/jim-2021-001952] [PMID:  34706925]

[17]
Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther  2021; 12(1): 143-57.
 [http://dx.doi.org/10.1007/s13300-020-00981-0] [PMID:  33325008]

[18]
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet  2021; 398(10313): 1811-24.
 [http://dx.doi.org/10.1016/S0140-6736(21)02188-7] [PMID:  34672967]

[19]
Wilding JP. STEP 1+ 2: Signifikante Gewichtsreduktion unter Semaglutid vs. Placebo. J Med  2021; 384: 989-1002.

[20]
Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab  2019; 30(30): 72-130.
 [http://dx.doi.org/10.1016/j.molmet.2019.09.010] [PMID:  31767182]

[21]
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev  2017; 97(2): 721-66.
 [http://dx.doi.org/10.1152/physrev.00025.2016] [PMID:  28275047]

[22]
Zeigerer A, Sekar R, Kleinert M, Nason S, Habegger KM, Müller TD. Glucagon’s metabolic action in health and disease. Compr Physiol  2021; 11(2): 1759-83.
 [http://dx.doi.org/10.1002/cphy.c200013]

[23]
Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med  2005; 11(1): 90-4.
 [http://dx.doi.org/10.1038/nm1168] [PMID:  15619630]

[24]
Thomsen C, Rasmussen O, Lousen T, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr  1999; 69(6): 1135-43.
 [http://dx.doi.org/10.1093/ajcn/69.6.1135]

[25]
Kim MY, Choi SW, Chung SK. Antioxidative flavonoids from the garlic (Allium sativum L.) shoot. Food Sci Biotechnol  2000; 9(4): 199-203.

[26]
Gameiro A, Reimann F, Habib AM, et al. The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol  2005; 569(3): 761-72.
 [http://dx.doi.org/10.1113/jphysiol.2005.098962] [PMID:  16223757]

[27]
Reimann F, Williams L, da Silva Xavier G, Rutter GA, Gribble FM. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia  2004; 47(9): 1592-601.
 [http://dx.doi.org/10.1007/s00125-004-1498-0] [PMID:  15365617]

[28]
Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol  1996; 31(7): 665-70.
 [http://dx.doi.org/10.3109/00365529609009147]

[29]
Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. The glucagon receptor family. Pharmacol Rev  2003; 55(1): 167-94.
 [http://dx.doi.org/10.1124/pr.55.1.6]

[30]
Novikoff A, O’Brien SL, Bernecker M, et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab  2021; 49: 101181.
 [http://dx.doi.org/10.1016/j.molmet.2021.101181]

[31]
Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM. B-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells. Proceedings of the national academy of sciences.  6614-9.
 [http://dx.doi.org/10.1073/pnas.0710402105]

[32]
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology  2014; 155(4): 1280-90.
 [http://dx.doi.org/10.1210/en.2013-1934]

[33]
Richards P, Parker HE, Adriaenssens AE, et al. Identification and characterization of GLP-1 receptor–expressing cells using a new transgenic mouse model. Diabetes  2014; 63(4): 1224-33.
 [http://dx.doi.org/10.2337/db13-1440]

[34]
Willms BE, Werner JE, Holst JJ, Orskov C, Creutzfeldt WE, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab  1996; 81(1): 327.
 [http://dx.doi.org/10.1210/jcem.81.1.8550773]

[35]
Canfield RL, Henderson CR Jr, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med  2003; 348(16): 1517-26.
 [http://dx.doi.org/10.1056/NEJMoa022848] [PMID:  12700371]

[36]
Kapodistria K, Tsilibary EP, Kotsopoulou E, Moustardas P, Kitsiou P. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis. J Cell Mol Med  2018; 22(6): 2970-80.
 [http://dx.doi.org/10.1111/jcmm.13259] [PMID:  29524296]

[37]
Liao P, Yang D, Liu D, Zheng Y. GLP-1 and ghrelin attenuate high glucose/high lipid-induced apoptosis and senescence of human microvascular endothelial cells. Cell Physiol Biochem  2017; 44(5): 1842-55.
 [http://dx.doi.org/10.1159/000485820] [PMID:  29224011]

[38]
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes  1999; 48(12): 2270-6.
 [http://dx.doi.org/10.2337/diabetes.48.12.2270]

[39]
During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med  2003; 9(9): 1173-9.
 [http://dx.doi.org/10.1038/nm919] [PMID:  12925848]

[40]
Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes  2010; 59(7): 1765-70.
 [http://dx.doi.org/10.2337/db09-1414]

[41]
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab  2018; 18(18): 3-14.
 [http://dx.doi.org/10.1016/j.molmet.2018.09.009] [PMID:  30473097]

[42]
Frias JP, Bastyr EJ III, Vignati L, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab  2017; 26(2): 343-352.e2.
 [http://dx.doi.org/10.1016/j.cmet.2017.07.011]

[43]
Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab  2020; 22(6): 938-46.
 [http://dx.doi.org/10.1111/dom.13979] [PMID:  31984598]

[44]
Tschöp MH, Finan B, Clemmensen C, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab  2016; 24(1): 51-62.
 [http://dx.doi.org/10.1016/j.cmet.2016.06.021]

[45]
Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab  2009; 11(5): 498-505.
 [http://dx.doi.org/10.1111/j.1463-1326.2008.00992.x] [PMID:  19187286]

[46]
Andersen JT, Dalhus B, Cameron J, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun  2012; 3(1): 610.
 [http://dx.doi.org/10.1038/ncomms1607] [PMID:  22215085]

[47]
Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med  2003; 197(3): 315-22.
 [http://dx.doi.org/10.1084/jem.20021829] [PMID:  12566415]

[48]
Kim J, Bronson CL, Hayton WL, et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol  2006; 290(2): G352-60.
 [http://dx.doi.org/10.1152/ajpgi.00286.2005] [PMID:  16210471]

[49]
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne)  2019; 10: 155.
 [http://dx.doi.org/10.3389/fendo.2019.00155] [PMID:  31031702]

[50]
Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia  2002; 45(2): 195-202.
 [http://dx.doi.org/10.1007/s00125-001-0719-z] [PMID:  11935150]

[51]
Elks CE, Scott RA. The long and short of telomere length and diabetes. Diabetes  2014; 63(1): 65-7.
 [http://dx.doi.org/10.2337/db13-1469] [PMID:  24357701]

[52]
Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci  2016; 105(2): 460-75.
 [http://dx.doi.org/10.1016/j.xphs.2015.11.015] [PMID:  26869412]

[53]
Digilio G, Barbero L, Bracco C, et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2. J Am Chem Soc  2003; 125(12): 3458-70.
 [http://dx.doi.org/10.1021/ja021264j] [PMID:  12643708]

[54]
Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin  2010; 26(1): 231-8.
 [http://dx.doi.org/10.1185/03007990903421994] [PMID:  19921965]

[55]
Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med  2018; 10(467): eaar7047.
 [http://dx.doi.org/10.1126/scitranslmed.aar7047] [PMID:  30429357]

[56]
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract  2017; 3(1): 3-14.
 [http://dx.doi.org/10.1002/osp4.84] [PMID:  28392927]

[57]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type  2016; 2: 1834-44.

[58]
Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol  2021; 20(1): 189.
 [http://dx.doi.org/10.1186/s12933-021-01366-8] [PMID:  34526024]

[59]
FDA FDA Approves New Drug Treatment for Chronic Weight
 Management, First Since 2014. (2021). FDA website in the section
 of News & Events for Human Drugs. FDA approves weight management
 drug for patients aged 12 and older. 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older

[60]
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2•4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet  2021; 397(10278): 971-84.
 [http://dx.doi.org/10.1016/S0140-6736(21)00213-0] [PMID:  33667417]

[61]
Finan B, Müller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschöp MH. Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med  2016; 22(5): 359-76.
 [http://dx.doi.org/10.1016/j.molmed.2016.03.005] [PMID:  27038883]

[62]
DiGruccio MR, Mawla AM, Donaldson CJ, et al. Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets. Mol Metab  2016; 5(7): 449-58.
 [http://dx.doi.org/10.1016/j.molmet.2016.04.007] [PMID:  27408771]

[63]
Vilsbøll T, Agersø H, Lauritsen T, et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept  2006; 137(3): 168-72.
 [http://dx.doi.org/10.1016/j.regpep.2006.07.007] [PMID:  16934887]

[64]
Yip RGC, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology  1998; 139(9): 4004-7.
 [http://dx.doi.org/10.1210/endo.139.9.6288] [PMID:  9724057]

[65]
Mantelmacher FD, Zvibel I, Cohen K, Epshtein A, Pasmanik-Chor M, Vogl T. An enteroendocrine-myeloid cell S100A8/A9 axis controls inflammation and body weight. Nat Metab  2019; 158: 69.

[66]
Metzger VL, Baker RJ, Schingoethe DJ. Responses of rumen microflora to high-concentrate low-roughage diets containing whey products. J Dairy Sci  1976; 59(10): 1769-75.
 [http://dx.doi.org/10.3168/jds.S0022-0302(76)84436-0] [PMID:  824331]

[67]
Dowsett GKC, Lam BYH, Tadross JA, et al. A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing. Mol Metab  2021; 53: 101240.
 [http://dx.doi.org/10.1016/j.molmet.2021.101240] [PMID:  33962048]

[68]
Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes  2011; 60(12): 3103-9.
 [http://dx.doi.org/10.2337/db11-0979] [PMID:  21984584]

[69]
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest  1993; 91(1): 301-7.
 [http://dx.doi.org/10.1172/JCI116186] [PMID:  8423228]

[70]
Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia  2009; 52(2): 199-207.
 [http://dx.doi.org/10.1007/s00125-008-1195-5] [PMID:  19037628]

[71]
Stensen S, Gasbjerg LS, Helsted MM, Hartmann B, Christensen MB, Knop FK. GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications. Peptides  2020; 125: 170197.
 [http://dx.doi.org/10.1016/j.peptides.2019.170197] [PMID:  31715213]

[72]
Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab  2020; 31(6): 410-21.
 [http://dx.doi.org/10.1016/j.tem.2020.02.006] [PMID:  32396843]

[73]
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab  2013; 17(6): 819-37.
 [http://dx.doi.org/10.1016/j.cmet.2013.04.008] [PMID:  23684623]

[74]
Campbell JE. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. Mol Metab  2021; 46: 101139.
 [http://dx.doi.org/10.1016/j.molmet.2020.101139] [PMID:  33290902]

[75]
Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes  1979; 28(12): 1141-2.
 [http://dx.doi.org/10.2337/diab.28.12.1141] [PMID:  510813]

[76]
Kim SJ, Nian C, McIntosh CHS. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res  2010; 51(11): 3145-57.
 [http://dx.doi.org/10.1194/jlr.M006841] [PMID:  20693566]

[77]
Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest  1981; 68(4): 1106-7.
 [http://dx.doi.org/10.1172/JCI110335] [PMID:  7287903]

[78]
Kim SJ, Nian C, McIntosh CHS. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem  2007; 282(12): 8557-67.
 [http://dx.doi.org/10.1074/jbc.M609088200] [PMID:  17244606]

[79]
Thondam SK, Daousi C, Wilding JPH, et al. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. Am J Physiol Endocrinol Metab  2017; 312(3): E224-33.
 [http://dx.doi.org/10.1152/ajpendo.00347.2016] [PMID:  28073779]

[80]
Delong T, Baker RL, Reisdorph N, et al. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes  2011; 60(9): 2325-30.
 [http://dx.doi.org/10.2337/db11-0288] [PMID:  21734016]

[81]
Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7–36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol  1991; 130(2): 267-72.
 [http://dx.doi.org/10.1677/joe.0.1300267] [PMID:  1919397]

[82]
Beck B, Max JP. Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat. Regul Pept  1983; 7(1): 3-8.
 [http://dx.doi.org/10.1016/0167-0115(83)90276-8] [PMID:  6359287]

[83]
Gill RK, Saksena S, Tyagi S, et al. Serotonin inhibits Na+/H+ exchange activity via 5-HT4 receptors and activation of PKCα in human intestinal epithelial cells. Gastroenterology  2005; 128(4): 962-74.
 [http://dx.doi.org/10.1053/j.gastro.2005.02.011] [PMID:  15825078]

[84]
Golley RK, Maher CA, Matricciani L, Olds TS. Sleep duration or bedtime? Exploring the association between sleep timing behaviour, diet and BMI in children and adolescents. Int J Obes  2013; 37(4): 546-51.
 [http://dx.doi.org/10.1038/ijo.2012.212] [PMID:  23295498]

[85]
Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA  1999; 96(26): 14843-7.
 [http://dx.doi.org/10.1073/pnas.96.26.14843] [PMID:  10611300]

[86]
Joo E, Harada N, Yamane S, et al. Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet–fed mice. Diabetes  2017; 66(4): 868-79.
 [http://dx.doi.org/10.2337/db16-0758] [PMID:  28096257]

[87]
Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab  2021; 33(4): 833-844.e5.
 [http://dx.doi.org/10.1016/j.cmet.2021.01.015] [PMID:  33571454]

[88]
Beaudry JL, Kaur KD, Varin EM, et al. Physiological roles of the GIP receptor in murine brown adipose tissue. Mol Metab  2019; 28: 14-25.
 [http://dx.doi.org/10.1016/j.molmet.2019.08.006] [PMID:  31451430]

[89]
Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med  2018; 10(472): eaat3392.
 [http://dx.doi.org/10.1126/scitranslmed.aat3392] [PMID:  30567927]

[90]
Holst JJ, Rosenkilde MM. Recent advances of GIP and future horizons. Peptides  2020; 125: 170230.
 [http://dx.doi.org/10.1016/j.peptides.2019.170230] [PMID:  31838219]

[91]
Baldassano S, Gasbjerg LS, Kizilkaya HS, Rosenkilde MM, Holst JJ, Hartmann B. Increased body weight and fat mass after subchronic GIP receptor antagonist, but not GLP-2 receptor antagonist, administration in rats. Front Endocrinol (Lausanne)  2019; 10: 492.
 [http://dx.doi.org/10.3389/fendo.2019.00492] [PMID:  31447774]

[92]
Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab  2019; 20: 51-62.
 [http://dx.doi.org/10.1016/j.molmet.2018.12.001] [PMID:  30578168]

[93]
Kaneko K, Fu Y, Lin HY, et al. Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Invest  2019; 129(9): 3786-91.
 [http://dx.doi.org/10.1172/JCI126107] [PMID:  31403469]

[94]
Svendsen B, Capozzi ME, Nui J, et al. Pharmacological antagonism of the incretin system protects against diet-induced obesity. Mol Metab  2020; 32: 44-55.
 [http://dx.doi.org/10.1016/j.molmet.2019.11.018] [PMID:  32029229]

[95]
Adriaenssens AE, Gribble FM, Reimann F. The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides  2020; 125: 170194.
 [http://dx.doi.org/10.1016/j.peptides.2019.170194] [PMID:  31697967]

[96]
Holst JJ, Rosenkilde MM. GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists. J Clin Endocrinol Metab  2020; 105(8): e2710-6.
 [http://dx.doi.org/10.1210/clinem/dgaa327] [PMID:  32459834]

[97]
Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight  2020; 5(17): e140532.
 [http://dx.doi.org/10.1172/jci.insight.140532] [PMID:  32730231]

[98]
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med  2001; 111(8) (Suppl. 8A): 106-12.
 [http://dx.doi.org/10.1016/S0002-9343(01)00849-X] [PMID:  11749934]

[99]
Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology  2008; 149(8): 4059-68.
 [http://dx.doi.org/10.1210/en.2007-1743] [PMID:  18420740]

[100]
Zhou Z, Subramanian P, Sevilmis G, et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab  2011; 13(5): 592-600.
 [http://dx.doi.org/10.1016/j.cmet.2011.02.016] [PMID:  21531341]

[101]
Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet  2021; 398(10300): 583-98.
 [http://dx.doi.org/10.1016/S0140-6736(21)01443-4] [PMID:  34370970]

[102]
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med  2021; 385(6): 503-15.
 [http://dx.doi.org/10.1056/NEJMoa2107519] [PMID:  34170647]

[103]
Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet  2021; 398(10295): 143-55.
 [http://dx.doi.org/10.1016/S0140-6736(21)01324-6] [PMID:  34186022]

[104]
Dahl D, Onishi Y, Norwood PA, Huh R, Patel H, Rodriguez A. 80-LB: tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5). Diabetes  2021; 70 (Supplement_1): 80-LB.

[105]
Libianto R, Ekinci EI. New agents for the treatment of type 2 diabetes. Crit Care Clin  2019; 35(2): 315-28.
 [http://dx.doi.org/10.1016/j.ccc.2018.11.007] [PMID:  30784612]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115733998256797231009062744	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies

Abstract Play Pause

Related Journals

Related Books

Abstract
